Endoron Medical, a medtech company specializing in innovative endograft stapling solutions for the endovascular repair of abdominal aortic aneurysms, announced the successful closing of its $10 million Series A funding round. This funding round was led by Sofinnova Partners, with significant matching contributions from the European Innovation Council Fund (EIC Fund).
The funding will accelerate the clinical validation of Endoron’s flagship product – which is the catheter-based EndoStapling solution Aortoseal – as it progresses through its Investigational Device Exemption (IDE) approved Early Feasibility Study (EFS).
Endoron is at the forefront of developing advanced technologies for the endovascular repair of abdominal aortic aneurysms (AAA) and its technology addresses the critical challenges of sealing and securing endografts used in minimally invasive AAA repairs, particularly in complex procedures. And Endoron’s stapling mechanism ensures complete sealing of endografts while securely anchoring them, preventing long-term migration and endoleaks, thus reducing the need for highly invasive, high-mortality open surgeries.
With the successful completion of the funding round, Endoron is well-positioned to capitalize on the growing market opportunity to drive innovation in endovascular care. And the company remains committed to advancing endovascular repair solutions to improve patient outcomes.
KEY QUOTES:
“Sofinnova Partners are the go-to investors within medtech. They bring a wealth of operational experience working with high-growth companies like ours. With their continued support, I am confident we will reach key clinical and regulatory milestones as we advance our EndoStapling technology towards the clinic. The EIC’s participation further solidifies our commitment to bringing this innovative solution to the European market.”
- Ronit Harpaz, co-founder and CEO of Endoron
“Endoron is a clear example of Sofinnova Partners MD Start’s acceleration strategy which identifies promising innovation at the earliest stages and provides capital as well as operational expertise via our team of serial entrepreneurs. We believe that Endoron’s innovative EndoStapling has the potential to revolutionize endovascular repair of AAA, and we are excited to support them in their journey.”
- Cécile Dupont, Partner at Sofinnova Partners’ medtech accelerator, MD Start
“We are very happy to participate in this funding round for Endoron. EIC Fund’s investment will help them advance their endovascular repair solution and reduce complications and reinterventions for patients.”
- Svetoslava Georgieva, Chair of the EIC Fund Board
